Allos Therapeutics, Inc. is one of the leading biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. FOLOTYN is the first and only drug approved in the U.S. for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Allos is also exploring the potential of FOLOTYN in other indications. Additionally, the data demonstrated that promising results were observed in patients who responded to treatment with FOLOTYN and proceeded to receive SCT as initial subsequent therapy. Of the 109 patients evaluable for response, 6 proceeded to SCT after responding to FOLOTYN. Thus, responses to FOLOTYN permitted patients to proceed to a potential curative transplant option. This analysis also underscores the important role FOLOTYN for PTCL patients who have failed to respond to prior therapies, progressed after prior autologous stem cell transplant and as a bridge to stem cell transplant for patients who respond to FOLOTYN therapy.

Related Articls:

1. Facet Biotech Reports Elotuzumab Data (NASDAQ:FACT)
2. Exelixis PI3K Interim Data (NASDAQ:EXEL)
3. Orexigen’s New Data (NASDAQ:OREX)

Related Articls:

1. Sangamo BioSciences Offering (NASDAQ:SGMO)
2. Shares of Amicus Drop (NASDAQ:FOLD)
3. Bionovo’s New Offering (NASDAQ:BNVI)

The news had a catalyst effect on the stock market and in no time Allos Therapeutics’ shares went up high which provide a great boost to Allos Therapeutics. In the morning trading, shares of Allos Therapeutics went up 4.3 percent and closed at $8.50. The company has said that Food and Drug Administration of the United States of America has granted them with accelerated approval, which will allow Allos Therapeutics to market Folotyn to use in patients whose cancer has not responded to earlier treatments. The company said that they will market Folotyn soon and the drug should be available in the market by October 2009.

Members of the FDA advisory panel said that the approval was accelerated because currently there are no treatments for patients suffering from PTCL and hence the decision had to be taken quickly. It is also been said that the FDA approved Folotyn because they saw that the patients treated with Folotyn had their tumors shrink considerably which made it easier for FDA to approve Folotyn in such a short span of time. FDA panel has further stated that Allos Therapeutics will conduct additional clinical trials to further define the benefits of Folotyn and whether Folotyn can extend survival.

Related Articls:

1. Discovery Labs – FDA meet for Surfaxin approval (DSCO)
2. Eye Drops Win Unanimous FDA Approval (Nasdaq: ISTA)
3. Clolar Gets Cool Reception From FDA and up for Approval (GENZ, VION)